San Diego, CA -- (SBWIRE) -- 01/09/2024 -- PTC Therapeutics, Inc. is under investigation over possible securities laws violations in connection with certain financial statements.

Investors who purchased shares of PTC Therapeutics, Inc. (NASDAQ: PTCT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by PTC Therapeutics, Inc. (NASDAQ: PTCT regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

South Plainfield, NJ based PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. On September 15, 2023, PTC Therapeutics, Inc. issued a press release "announc[ing] . . . that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The negative opinion also applies to the renewal of the existing conditional authorization."

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) declined from $41.93 per share on September 07, 2023, to as low as $20.17 per share on October 04, 2023.

Those who purchased shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) have certain options and should contact the Shareholders Foundation.

About The Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com